GlassScriptPhysician profile
Tammy Dunn
NPI 1407396146
$13,529.37
in general payments reported to CMS, 2019-2025
28 companies · $4,132 in 2025
The $4,132 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,365 · 2022: $1,906 · 2023: $3,186 · 2024: $2,941 · 2025: $4,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $49.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,208.63 |
| Education | $49.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,916.52 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,704.21 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,693.35 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $1,195.10 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $981.70 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $820.94 | 2021-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $502.37 | 2023-2025 | Auvelity |
| Lundbeck LLC | $360.70 | 2022-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $355.14 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $352.79 | 2023-2024 | Ultomiris, Soliris |
| Boston Scientific Corporation | $270.06 | 2023-2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $155.66 | 2024-2025 | Cobenfy |
| Biohaven Pharmaceuticals, INC. | $117.18 | 2021 | |
| Inari Medical, INC. | $113.46 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Impel Pharmaceuticals INC. | $113.40 | 2023 | Trudhesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $113.40 | 2024 | Injectafer |
| Novo Nordisk INC | $112.50 | 2022 | |
| Ucb, INC. | $107.10 | 2023 | Nayzilam |
| Neurelis, INC. | $91.82 | 2023 | Valtoco |
| Vanda Pharmaceuticals INC. | $75.23 | 2024-2025 | Fanapt, Hetlioz |
| Phathom Pharmaceuticals, INC. | $67.77 | 2025 | Voquezna |
| Eisai INC. | $62.87 | 2021-2022 | |
| Verona Pharma, INC. | $62.43 | 2025 | Ohtuvayre |
| Tactile Systems Technology INC | $47.67 | 2024 | Flexitouch Plus, Entre Plus |
| Mannkind Corporation | $43.94 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.84 | 2022 | |
| Corium, LLC | $34.01 | 2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $20.21 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.